For successful effector functions, it is imperative for CAR T cells to rapidly recognize tumor cells and facilitate CAR receptor binding with the CAR antigen (e.g., CD19, CD20, CD22, BCMA, etc.)expressed on tumor cells (154). This evidence concerns the gene CD22 and neoplasm.